Indication |
Used for aborting second-trimester pregnancy (between the twelfth
to eighteenth week of gestation) and in incomplete abortion or for
therapeutic abortion in cases of intrauterine fetal death and congenital
abnormalities incompatible with life. Also used at low-doses for
medically indicated induction of labor at term. Also injected
intra-arterially for use as a vasodilator to assist in angiography. |
Pharmacodynamics |
Dinoprost tromethamine is the tromethamine (THAM) salt of the naturally occurring prostaglandin F2alpha. Prostaglandin F2alpha has
several pharmacologic effects on the female reproductive system,
including stimulation of myometrial activity, relaxation of the cervix,
inhibition of steroidogenesis by corpora lutea, and can potentially lyse
corpora lutea. |
Mechanism of action |
Dinoprost tromethamine appears to act directly on the myometrium,
but this has not been completely established. Dinoprost stimulates
myometrial contractions (via its interaction with the prostaglandin
receptors) in the gravid uterus that are similar to the contractions
that occur in the term uterus during labor. These contractions are
usually sufficient to cause abortion. Uterine response to prostaglandins
increases gradually throughout pregnancy. Dinoprost also facilitates
cervical dilatation and softening. |
Absorption |
Slowly absorbed from the amniotic fluid into systemic circulation. |
Volume of distribution |
Not Available |
Protein binding |
Not Available |
Metabolism |
Enzymatic dehydrogenation primarily in the maternal lungs and also in the liver. |
Route of elimination |
Not Available |
Half life |
The half-life of dinoprost in amniotic fluid is 3 to 6 hours. The
plasma half-life of dinoprost after intravenous administration is
reported to be less than 1 minute. |
Clearance |
Not Available |
Toxicity |
Although overdose by intra-amniotic administration of dinoprost
has not been reported, exaggeration of the nausea, vomiting, and
diarrhea that occur with normal doses would be expected. |